Results 1 to 10 of about 15,930 (153)

Multicenter prospective study on the prevalence of colistin resistance in Escherichia coli: relevance of mcr-1-positive clinical isolates in Lombardy, Northern Italy

open access: yes, 2018
Luigi Principe,1 Aurora Piazza,2,3 Carola Mauri,1 Adriano Anesi,4 Silvia Bracco,5 Gioconda Brigante,6 Erminia Casari,7 Carlo Agrappi,8 Mariasofia Caltagirone,2 Federica Novazzi,2 Roberta Migliavacca,2 Laura Pagani,2 Francesco Luzzaro1 1Microbiology and ...
Anesi A   +12 more
core  

Colistin Resistance Mechanisms and Molecular Epidemiology of Enterobacter cloacae Complex Isolated from a Tertiary Hospital in Shandong, China

open access: yes
Zaifeng Si,1,2,* Shengmei Zhao,3,* Yingying Hao,3 Qian Wang,3 Yanfa Zhong,2 Yue Liu,3 Ran Chen,3 Yan Jin,3 Zhiming Lu1,3 1Department of Clinical Laboratory, Shandong Provincial Hospital, Cheeloo College of Medicine, Shandong University, Jinan ...
Liu Y   +8 more
core  

Management with colistin

open access: yesIndian Journal of Critical Care Medicine, 2010
openaire   +2 more sources

The Potentiation Activity of Azithromycin in Combination with Colistin or Levofloxacin Against Pseudomonas aeruginosa Biofilm Infection

open access: yes
Yuhang Wang,1,* Chunsun Li,2,* Huan Zhang,1 Yulong Chi,1 Yun Cai1 1Center of Medicine Clinical Research, Department of Pharmacy, Medical Supplies Center of PLA General Hospital, Beijing, People’s Republic of China; 2Laboratory of Department of ...
Li C, Zhang H, Cai Y, Wang Y, Chi Y
core  
Some of the next articles are maybe not open access.

Colistin—A Reappraisal

JAMA, 1963
COLISTIN, a polypeptide antibiotic closely related to polymyxin B, has been in use in the United States for approximately three years. Despite the accumulation of considerable clinical experience with this agent, it is still subject to a good deal of controversy.
R G, PETERSDORF, J J, PLORDE
openaire   +2 more sources

Reviving colistin

Nature Reviews Microbiology, 2023
openaire   +2 more sources

Colistin

Reactions Weekly, 2022
Lipika Singhal   +2 more
  +4 more sources

Home - About - Disclaimer - Privacy